Wow, management really worked hard and pushed the boat out on that not so detailed rebuttal, lol :)). I expect the shorts to reign for a few more days but after the dust has settled this stock might be worth a speculative buy when it hits $1.5-2.0.
A clue that their drug does not really work ...
'The drug did not significantly improve flow of urine, the secondary goal of the study, the company said. Men who suffer from enlarged prostate often have problems urinating.'
Their drug works by destructive necrosis whereas NYMX's uses the more efficient natural apoptosis.
p.s. the only (temporary) false positives was on the placebo which you should already know as this has already been discussed while you was here before.
They did not mislead last time as the long term results of the same Ph3 trials proved. Don't you know how to distinguish general trivial ambulance-chasing lawsuits from real problems ?
So you short this week oh classless trader ? You was long on this stock for months ...
norenar07 • Oct 16, 2015 10:18 AM
Big Tip: Nymox Pharma. NYMX ---keep on watch list--- completed PH3 - prostate cancer drug....
It shows little or no side affects - awaiting other final results to submit to FDA - - may be big upside in near future.
It killed the prostrate cancer completely and utterly stone dead ! ....
Based on biopsy progression the proportion of patients who progressed on biopsy and required biopsy progression-related surgery or radiotherapy in the cross-over group (0%) at 18 months was significantly less than in the control group (p.LT..03).
The cross-over group patients received randomized fexapotide 15 mg or 2.5 mg in a single treatment targeted toward the positive baseline cancer focus identified in initial positive biopsies. There were no cases in either of the 2 fexapotide dosage level treatment groups with biopsy progression at 18 months (p.LT.03).
In addition to the positive clinical progression results, the primary endpoint of the study (re-biopsy absence of tumor in the initially positive biopsy baseline area of the prostate) also reached statistical significance (p.LT.03) in the cross-over study. At the 18 month assessments, the post-treatment biopsy taken from the treated area of the prostate which was initially positive at baseline, showed absence of tumor (tumor presence in re-biopsy of baseline positive focus n=0) in the cross-over treated patients, which was statistically significant compared to controls (p.LT.03).
My guess is they would not have bothered to pre-announce the Ph2 Cancer result if it was not going to be good. They did the same previewing the Ph3 BPH result and we know how that turned out.
NYMX has already passed whereas SPHS failed its Ph3 in December. Now get lost back to your loser stock board.
you don't know the difference between Institutions and Insiders but then again what does one expect from bag-holders of a failed company.
your already failed drug works by an inferior necrosis method and it will fail again with the above BS your personal fantasy. Now FO back to your own board and stop pumping your fantasy garbage here, no-one is interested.
you still peddling your sphs junk here ? You must be desperate ... again. The reason sphs stock is nowhere is because they failed their last endpoint and they are prolonging the agony of their death spiral now.
Since you have not answered why you did not sell when it went over 2 recently I can only conclude you expect it to go much higher in the future even if you are #$%$ off with management.
This still does not explain why you did not get out at a profit in late September, just 3 weeks ago, when you could have. Why did you not sell then if you are so unhappy ?
'I have 80,000 shares that I would sell you this morning at $1.70 if you are interested.'
Why did you not sell in late September when the price was well over that for three days in a row with volume. This part of your story just does not add up.